Morgan, Leedman Join BlinkLab Board for AI Autism Detection


BlinkLab, the groundbreaking early detection diagnostic tool for Autism and other neurological disorders, is pleased to announce the appointments of Jane Morgan as a Non-Executive Director and Brian Leedman as Chairman of the Board. These significant additions to the board come as BlinkLab prepares for listing on the Australian Securities Exchange (ASX), with Westar Capital as the lead manager for the IPO.

Jane Morgan, Founder, and Director of Investor and Media Relations firm JMM, is a seasoned professional with a wealth of experience in strategic communications and investor relations. Her extensive background makes her an invaluable asset to BlinkLab's leadership team.

Brian Leedman, a highly respected figure in the financial and business community, will serve as Chairman of the Board. With a remarkable career spanning various industries, including finance, technology, and healthcare, Mr. Leedman brings a depth of knowledge and a strategic perspective that will greatly benefit BlinkLab. He is the co-founder and Executive Director of highly successful digital healthcare company, ResApp Health (ASX:RAP) that was acquired by Pfizer in September 2022 for its regulatory approved cough-based respiratory disease screening test using only a smartphone.

BlinkLab, a Princeton University technology founded two years ago by Dr. Henk-Jan Boele (MD, PhD) and his scientific team, is at the forefront of early diagnosis of autism and ADHD. The company has a fully developed a neurometric testing platform that leverages computer vision, machine learning, and artificial intelligence. The platform utilizes conventional smartphones and tablets as neurological data collection tools.

Currently, the diagnosis of neurological disorders can take up to a year and a half to complete, requiring the approval of several clinical specialists. This process typically occurs when the patient is five years old, which is generally considered as too late for effective therapeutic treatment. BlinkLab, however, is revolutionizing this paradigm by reducing the diagnostic evaluation process to one or two 15-minute smartphone based neurometric tests that potentially can bring down the diagnostic age to as low as 18 months of age, yet with an accuracy above currently FDA approved products. This breakthrough promises to make a significant impact by allowing therapeutic treatment at an age when neural pathways are still forming in the brain, facilitating effective rewiring of these pathways and significantly bringing down medical expenses for families and healthcare systems.

The ASX listing will raise an estimated A$6-8 million, providing BlinkLab with the necessary resources to pursue its FDA registrational study over the next 24 months. This milestone marks a pivotal moment in the company's journey towards improving the lives of individuals affected by neurological disorders including autism.

BlinkLab's association with Jane Morgan and Brian Leedman underscores its commitment to excellence and innovation in the field of early diagnosis and intervention for neurological disorders. With their wealth of experience and strategic vision, Ms. Morgan and Mr. Leedman will play vital roles in guiding BlinkLab's mission to change the status quo in neurological disorder diagnosis and treatment.

Key Facts:

Scientific Report published in Nature, 18 December 2023:

Accessible and reliable neurometric testing in humans using a smartphone platform

About us:

BlinkLab is a Princeton University technology founded by Dr. Henk-Jan Boele and Dr. Anton Uvarov and their scientific team, specializing in early detection and diagnosis of neurological disorders using innovative technology. The company's mission is to reduce the age of diagnosis and enable more effective therapeutic treatment for individuals with neurological disorders.


/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).